Skip to main content
SpringerLink
Log in

Prostate Cancer Prevention: Agent Development Strategies

  • Chapter
  • First Online:
Prostate Cancer Prevention

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 202))

Abstract

Despite advances in surgery, radiation, and medical therapy over the past decade and the widespread adoption of PSA screening, prostate cancer continues to be the second leading cause of cancer death in men in the United States. Invasive cancer is the end result of carcinogenesis, a chronic process occurring over many years driven by genetic and epigenetic alterations. The protracted nature of this transformation to the malignant phenotype provides an opportunity to intervene pharmacologically to prevent, reverse, or delay carcinogenesis, i.e. chemoprevention. Herein, we describe the unique features of cancer prevention, as opposed to cancer treatment, agent development clinical trials, and provide a summary of the ongoing research in this field being supported by the National Cancer Institute.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Algotar AM, Stratton MS, Ahmann FR et al (2013) Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate 73(3):328–335

    Google Scholar 

  • Andriole GL, Bostwick DG, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–202

    Google Scholar 

  • Bostwick DG, Qian J (2001) Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology 58:91–93

    Article  CAS  PubMed  Google Scholar 

  • Carducci MA WJ, Heath E, et al (2007) A randomized, placebo-controlled trial of celecoxib in men prior to receiving prostatectomy for clinically localized adenocarcinoma of the prostate: evaluation of drug-specific biomarker modulation. Suppl J Clin Oncol ASCO Annu Meet Proc 25:235s

    Google Scholar 

  • Carter HB, Kettermann A, Warlick C et al (2007) Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178:2359–2364 (Discussion 64–65)

    Google Scholar 

  • Chan JM, Weinberg V, Magbanua MJ et al (2011) Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes Control 22:141–150

    Article  PubMed Central  PubMed  Google Scholar 

  • Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178:S14–S19

    Article  PubMed Central  PubMed  Google Scholar 

  • De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155:1985–1992

    Article  PubMed  Google Scholar 

  • Huang X, Chen S, Xu L et al (2005) Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 65:3470–3478

    CAS  PubMed  Google Scholar 

  • Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428

    Article  CAS  PubMed  Google Scholar 

  • Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87:159–170

    Article  CAS  PubMed  Google Scholar 

  • Klein EA, Thompson IM Jr, Tangen CM et al (2011) Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 306:1549–1556

    Article  CAS  PubMed  Google Scholar 

  • Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131

    Google Scholar 

  • Kronz JD, Allan CH, Shaikh AA, Epstein JI (2001) Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 25:1079–1085

    Article  CAS  PubMed  Google Scholar 

  • Kumar NB, Krischer JP, Allen K et al (2007) A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer 59:163–168

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kumar N (2011) Personal communication

    Google Scholar 

  • Lippman SM, Hong WK (2002) Cancer prevention science and practice. Cancer Res 62:5119–5125

    CAS  PubMed  Google Scholar 

  • Lippman SM, Klein EA, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 301:39–51

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Marshall JR, Tangen CM, Sakr WA et al (2011) Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) 4:1761–1769

    Article  CAS  Google Scholar 

  • Nguyen MM, Ahmann FR, Nagle RB et al (2012) Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila) 5:290–298

    Article  CAS  Google Scholar 

  • Ozten-Kandas N, Bosland MC (2011) Chemoprevention of prostate cancer: natural compounds, antiandrogens, and antioxidants—in vivo evidence. J Carcinog 10:27

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Parnes HL, House MG, Kagan J, Kausal DJ, Lieberman R (2004) Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention Portfolio. J Urol 171:S68–74. Discussion S5

    Google Scholar 

  • Renan MJ (1993) How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 7:139–146

    Article  CAS  PubMed  Google Scholar 

  • Sabichi AL, Lee JJ, Taylor RJ et al (2006) Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a southwest oncology group study. Clin Cancer Res 12:2178–2184

    Article  CAS  PubMed  Google Scholar 

  • Schulman CC, Zlotta AR, Denis L, Schroder FH, Sakr WA (2000) Prevention of prostate cancer. Scand J Urol Nephrol Suppl 205:50–61

    Google Scholar 

  • Simoneau AR, Gerner EW, Nagle R et al (2008) The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomark Prev 17:292–299

    Google Scholar 

  • Singer EA, Kaushal A, Turkbey B, Couvillon A, Pinto PA, Parnes HL (2012) Active surveillance for prostate cancer: past, present and future. Curr Opin Oncol 24:243–250

    Article  PubMed  Google Scholar 

  • Sporn MB, Suh N (2000) Chemoprevention of cancer. Carcinogenesis 21:525–530

    Google Scholar 

  • Sporn MB, Suh N (2002) Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2:537–543

    Article  CAS  PubMed  Google Scholar 

  • Stratton MS, Algotar AM, Ranger-Moore J et al (2010) Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila) 3:1035–1043

    Article  CAS  Google Scholar 

  • Thompson IM, Ankerst DP, Chi C et al (2006) Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 98:529–534

    Google Scholar 

  • Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224

    Article  CAS  PubMed  Google Scholar 

  • Weight CJ, Kim SP, Karnes RJ, Bergstralh EJ, Cheville JC, Leibovich BC (2012) A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis. Urology 80(484):e17–e22

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Prevention, 9609 Medical Center Drive, National Cancer Institute, Bethesda, MD, 20892-9783, USA

    Howard L. Parnes

  2. Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA

    Margaret G. House & Joseph A. Tangrea

Authors
  1. Howard L. Parnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margaret G. House
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph A. Tangrea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howard L. Parnes .

Editor information

Editors and Affiliations

  1. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine Queen Mary University of London, London, United Kingdom

    Jack Cuzick

  2. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine Queen Mary University of London, London, United Kingdom

    Mangesh A. Thorat

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Parnes, H.L., House, M.G., Tangrea, J.A. (2014). Prostate Cancer Prevention: Agent Development Strategies. In: Cuzick, J., Thorat, M. (eds) Prostate Cancer Prevention. Recent Results in Cancer Research, vol 202. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45195-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-45195-9_15

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-45194-2

  • Online ISBN: 978-3-642-45195-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation